Table 2. Baseline characteristics of the studied patient group (N = 129).
Data is presented as mean ± SD unless otherwise indicated.
| Parameter | Total | Major benefit | Minor benefit | p-value | |
|---|---|---|---|---|---|
| Assessed ITT-collective [N (%)] | 129 (100%) | 73 (100%) | 56 (100%) | . | |
| Female Gender [N (%)] | 69 (53.5%) | 39 (53.4%) | 30 (53.6%) | 1.000 | |
| Length of the intervention[N (%)] | 12 months9 months6 months | 54 (41.9%)32 (24.8%)43 (33.3%) | 37 (50.7%)19 (26%)17 (23.3%) | 17 (30.4%)13 (23.2%)26 (46.4%) | 0.017 |
| Age | 76.4 ± 6.3 | 76.7 ± 6.2 | 76.1 ± 6.4 | 0.694 | |
| eGFR | 55.6 ± 21.5 | 52.6 ± 21.3 | 59.6 ± 21.3 | 0.071 | |
| Mean summated baselineMAI score per patient | 31.3 ± 24.8 | 40.0 ± 26.8 | 19.9 ± 16.0 | <0.001 | |
| Number of drugs | 9.4 ± 3.2 | 10.5 ± 3.4 | 8.1 ± 2.3 | <0.001 | |
| Number of differences between GP-prescribed and used drugs | 4.5 ± 3.5 | 5.4 ± 3.7 | 3.3 ± 2.8 | 0.001 | |
| CIRS-G severity index | 1.6 ± 0.4 | 1.7 ± 0.4 | 1.6 ± 0.4 | 0.090 | |
| Number of diagnoses | 13.1 ± 5.8 | 13.5 ± 6.3 | 12.6 ± 5.1 | 0.526 | |
| Number of health-care providers(specialists and hospitals) | 3.0 ± 2.1 | 3.2 ± 2.3 | 2.6 ± 1.7 | 0.167 | |
| Number of GP visits (during past 6 months) | 12.3 ± 8.4 | 12.0 ± 8.9 | 12.7 ± 7.7 | 0.396 |